Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Appointed director
Quarterly results
Diffusion Pharmaceuticals Inc. (DFFN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/29/2023 8-K/A Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: " ",
" ",
" "
08/17/2023 8-K Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra...
Docs: " ",
" ",
" ",
" ",
" ",
" ",
" ",
"INDEMNIFICATION AGREEMENT",
" ",
" "
08/14/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
08/09/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" ",
" "
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/03/2023 8-K Other Events  Interactive Data
08/03/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference BOSTON, MA – August 3, 2023 – EIP Pharma Inc. , a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9 at 4:00 p.m. ET. The Company will also be holding 1x1 meetings at the conference. A live webcast of the presentation, along with accompanying slides, can be accessed here . About EIP Pharma EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. EIP Pharma is currently developing neflamapimod, an investigatio..."
07/31/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/31/2023 8-K Quarterly results
07/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/13/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/11/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
05/19/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/19/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain...
Docs: "Separation Agreement and General Release, by and between Diffusion Pharmaceuticals Inc. and William K. Hornung"
05/15/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/15/2023 8-K Investor presentation
Docs: "Corporate Presentation"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EIP Pharma to Present at JMP Securities Life Sciences Conference BOSTON, MA – May 11, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Company’s senior management team will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 11:00 a.m. ET. The company will also be holding 1x1 meetings at the conference. A live webcast of the presentation, along with accompanying slides, can be accessed here, and will be available for replay for 90 days following the event. About EIP Pharma EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. EIP Pharma is currentl..."
05/10/2023 S-4 Form S-4 - Registration of securities, business combinations:
04/03/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/30/2023 8-K Quarterly results
03/24/2023 10-K Annual Report for the period ended December 31, 2022
12/30/2022 8-K Quarterly results
12/16/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/16/2022 8-K Quarterly results
12/06/2022 PRRN14A Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy